Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
clonidine alpha-1a adrenergic receptor small molecule NA drugbank Hypertensive disease[MeSHID:D006973]
Pheochromocytoma[MeSHID:D010673]
Malignant Neoplasms[MeSHID:D009369]
Attention deficit hyperactivity disorder[MeSHID:D001289]
Nicotine Dependence[MeSHID:D014029]
Diagnosis[MeSHID:D003933]
Patient Discharge[MeSHID:D010351]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Neuropathies[MeSHID:D003929]		 NA approved agonist
clonidine alpha-1b adrenergic receptor small molecule NA drugbank Hypertensive disease[MeSHID:D006973]
Pheochromocytoma[MeSHID:D010673]
Malignant Neoplasms[MeSHID:D009369]
Attention deficit hyperactivity disorder[MeSHID:D001289]
Nicotine Dependence[MeSHID:D014029]
Diagnosis[MeSHID:D003933]
Patient Discharge[MeSHID:D010351]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Neuropathies[MeSHID:D003929]		 NA approved agonist
clonidine alpha-1d adrenergic receptor small molecule NA drugbank Hypertensive disease[MeSHID:D006973]
Pheochromocytoma[MeSHID:D010673]
Malignant Neoplasms[MeSHID:D009369]
Attention deficit hyperactivity disorder[MeSHID:D001289]
Nicotine Dependence[MeSHID:D014029]
Diagnosis[MeSHID:D003933]
Patient Discharge[MeSHID:D010351]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Neuropathies[MeSHID:D003929]		 NA approved agonist
clonidine alpha-2a adrenergic receptor small molecule NA drugbank , DGIDB Hypertensive disease[MeSHID:D006973]
Pheochromocytoma[MeSHID:D010673]
Malignant Neoplasms[MeSHID:D009369]
Attention deficit hyperactivity disorder[MeSHID:D001289]
Nicotine Dependence[MeSHID:D014029]
Diagnosis[MeSHID:D003933]
Patient Discharge[MeSHID:D010351]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Neuropathies[MeSHID:D003929]		 1.04 approved agonist
clonidine alpha-2b adrenergic receptor small molecule NA drugbank , DGIDB Hypertensive disease[MeSHID:D006973]
Pheochromocytoma[MeSHID:D010673]
Malignant Neoplasms[MeSHID:D009369]
Attention deficit hyperactivity disorder[MeSHID:D001289]
Nicotine Dependence[MeSHID:D014029]
Diagnosis[MeSHID:D003933]
Patient Discharge[MeSHID:D010351]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Neuropathies[MeSHID:D003929]		 0.45 approved agonist
clonidine alpha-2c adrenergic receptor small molecule NA drugbank , DGIDB Hypertensive disease[MeSHID:D006973]
Pheochromocytoma[MeSHID:D010673]
Malignant Neoplasms[MeSHID:D009369]
Attention deficit hyperactivity disorder[MeSHID:D001289]
Nicotine Dependence[MeSHID:D014029]
Diagnosis[MeSHID:D003933]
Patient Discharge[MeSHID:D010351]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Neuropathies[MeSHID:D003929]		 0.46 approved agonist
clonidine membrane copper amine oxidase NA Successful target TTD , DGIDB Hypertensive disease[MeSHID:D006973]
Pheochromocytoma[MeSHID:D010673]
Malignant Neoplasms[MeSHID:D009369]
Attention deficit hyperactivity disorder[MeSHID:D001289]
Nicotine Dependence[MeSHID:D014029]
Diagnosis[MeSHID:D003933]
Patient Discharge[MeSHID:D010351]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Neuropathies[MeSHID:D003929]		 1.06 approved unknown
click here to return to the previous page